These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 3873871

  • 41. Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B beta-lactamase.
    Minami S, Akama M, Araki H, Watanabe Y, Narita H, Iyobe S, Mitsuhashi S.
    J Antimicrob Chemother; 1996 Mar; 37(3):433-44. PubMed ID: 9182100
    [Abstract] [Full Text] [Related]

  • 42. In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
    Weinstein RA, Nathan C, Delzell D, Kabins SA.
    Chemioterapia; 1987 Oct; 6(5):315-8. PubMed ID: 3123078
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests.
    Jones RN, Barry AL, Thornsberry C, Gerlach EH, Fuchs PC, Gavan TL, Sommers HM.
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():187-211. PubMed ID: 19802985
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Beta-lactamase stability of imipenem.
    Labia R, Morand A, Guionie M.
    J Antimicrob Chemother; 1986 Dec; 18 Suppl E():1-8. PubMed ID: 3493236
    [Abstract] [Full Text] [Related]

  • 48. In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms.
    Chen HY, Livermore DM.
    J Antimicrob Chemother; 1994 May; 33(5):949-58. PubMed ID: 8089068
    [Abstract] [Full Text] [Related]

  • 49. Antibacterial activity of T-5575, a novel 2-carboxypenam, and its stability to beta-lactamase.
    Matsumura N, Minami S, Mitsuhashi S.
    J Antimicrob Chemother; 1997 Jan; 39(1):31-4. PubMed ID: 9044025
    [Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Review of imipenem.
    Park SY, Parker RH.
    Infect Control; 1986 Jun; 7(6):333-7. PubMed ID: 3519499
    [Abstract] [Full Text] [Related]

  • 52. In-vitro and in-vivo antibacterial activity of imipenem against clinical isolates of bacteria.
    Mitsuhashi S.
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():53-64. PubMed ID: 6607914
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54. Synergy of imipenem--a novel carbapenem, and rifampin and ciprofloxacin against Pseudomonas aeruginosa, Serratia marcescens and Enterobacter species.
    Chin NX, Neu HC.
    Chemotherapy; 1987 Dec; 33(3):183-8. PubMed ID: 3109815
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. [Meropenem: microbiologic perspective].
    García-Rodríguez JA, García Sánchez E, Fresnadillo Martínez MJ.
    Enferm Infecc Microbiol Clin; 1997 Sep; 15 Suppl 1():2-7. PubMed ID: 9410064
    [Abstract] [Full Text] [Related]

  • 57. [Bacterial resistance against beta-lactam antibiotics].
    Andersen BM.
    Tidsskr Nor Laegeforen; 1990 Oct 20; 110(25):3233-9. PubMed ID: 2256036
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Comparison of in vitro activity of FCE 22101, a new penem, with those of other beta-lactam antibiotics.
    Wise R, Andrews JM, Danks G.
    Antimicrob Agents Chemother; 1983 Dec 20; 24(6):909-14. PubMed ID: 6607032
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.